COA in PROgress Boehringer Ingelheim GMBH

Patient-reported outcome measures – are there too many or too few?

Professors Michael Brundage and David Cella debate this question and deep-dive into a few patient prioritization measures on this week's all-new episode, including the criteria for validity, reliability, and scoring interpretability.

How do you create a good end-to-end patient centered drug development strategy? 

Join Sonya Eremenco and John Powers as they discuss why it's important to put patients at the heart of COA approaches – from concept to endpoint positioning, and the most crucial steps in between.

This week, we're putting the PRO in PROgress by discussing Patient Reported Outcomes with guests Paul Miller and Olivier Wong. In particular, how they're shaping the world of health technology assessment.

From introduction to interpretation, join Dan O’Connor and Chad Gwaltney as they explore how best to meet the expectations of regulatory authorities. Including: demystifying COA guidance documents and discussing how they became an integral part of the regulatory landscape.